Drugs.com - Clinical Trials

Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC

LAS VEGAS, April 26, 2025 – Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain...

Apr 30, 2025 - 23:43
 0
Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC
LAS VEGAS, April 26, 2025 – Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain...
Read More

Tags:

Previous Article

STAT+: Study: Lack of access to antibiotics for drug-resistant infections often ...

Next Article

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BC...

Related Posts

NIH Researchers Develop Eye Drops That Slow Vision Loss in Animals

NIH Researchers Develop Eye Drops That Slow Vision Loss...

Apr 26, 2025  0

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen’s Investigational Tau-Targeting Therapy BIIB080 ...

Apr 26, 2025  0

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile in a Once Daily Pill

Icotrokinra Results Show 75% of Adolescents with Plaque...

Apr 26, 2025  0